Greater China Strategy | Alpha Picks: February Conviction Calls Chinese equities recovered in January, with the HSI and MSCI China rising 6.9% and 5.0% mom, respectively. Given the supportive macro policy environment, we maintain a constructive view on the markets despite risk of further volatility in February. Accordingly, we are adding Alibaba, Ganfeng Lithium, and Minth to our BUY list, while adding Meituan to our SELL list. Indonesia Company Results | Bank Negara Indonesia (BBNI IJ/B...
Singapore equities delivered a strong January performance, with the STI rising 5.6% to fresh record highs amid heightened geopolitical tensions that drove flight-to-safety flows. Manufacturing activity remained in mild expansion, led by electronics and AI-related demand. Market/corporate catalysts during the month include REIT earnings, IPO interest in Catalist and continued strength in gold-linked counters.
Highlights To-C applications growth is accelerating among mega-cap players with super apps, while emerging unicorns focus on To-B and To-prosumers in specific AI scenarios/verticals and on physical AI in verticals such as mobility and smartphone. For the next 6-12 months, we are eyeing key AI narratives: a) roll-out of super apps leveraging on agentic AI, b) leading LLMs in specific verticals unlocking monetisation potential, and c) key drivers of cloud revenue growth. Over time, we expect fur...
Greater China Economics | PMI January PMI was below Bloomberg’s consensus, as the manufacturing PMI dipped to 49.2 (-0.9pt mom). The manufacturing output sub-index stayed marginally expansionary, while the new orders and new export orders sub-indices weakened. The purchase prices sub-index surged, pointing to higher cost pressure for manufacturers. The non-manufacturing PMI also fell to 49.4 (-0.8pt mom), mainly driven by a sharp contraction in the construction industry index. Large enterpri...
The appointment of Kevin Warsh as the new Fed Chair has strengthened the Fed’s credibility in fighting inflation, leading to an abrupt unwind for safe haven assets. Liquidity exiting safe haven assets, such as the Singapore dollar, could lead to firmer domestic interest rates in 2026. Maintain OVERWEIGHT. The Fed regaining its credibility is supportive of our thesis that banks benefit from the Goldilocks economy. BUY DBS (Target: S$68.95) and OCBC (Target: S$23.65). DBS provides an attractive 20...
Top Stories Strategy | Singapore Outlook The Singapore market outlook webinar for retail clients received over 200 attendees. We outlined our 2026 strategy, highlighting large-cap picks (DBS, GENS, KEP, SE), small-mid-cap selections (FEH, VALUE, RSTON, CAO), and top five S-REITs (CLAR, KREIT, LREIT, CAREIT, NTTDCR). Key questions include potential EQDP beneficiaries, small-mid-cap stocks, property counters, banks and REITS. Market Spotlight • US stocks were higher on Thursday, with the DJI...
The Singapore market outlook webinar for retail clients received over 200 attendees. We outlined our 2026 strategy, highlighting large-cap picks (DBS, GENS, KEP, SE), small-mid-cap selections (FEH, VALUE, RSTON, CAO), and top five S-REITs (CLAR, KREIT, LREIT, CAREIT, NTTDCR). Key questions include potential EQDP beneficiaries, small-mid-cap stocks, property counters, banks and REITS.
We expect Tencent’s revenue growth to remain solid at 13% yoy in 4Q25 despite macro headwinds and the ad-spend tax, continuing to benefit from inventory release and AI empowerment. We opine that near- to mid-term catalysts would include: a) multiple flagship new game launches in 2026, b) continued improvement in ad placement efficiency driven by AI, and c) the launch of AI-powered Mini Program code development tools on WeChat. Maintain BUY with an unchanged target price of HK$800.00.
Top Stories Sector Update | Healthcare At the recent investor conference, global investors viewed Chinese healthcare companies with increasing interest and optimism. Impressed by their advanced R&D pipelines and swift R&D-to-market execution capabilities, investors recognised Chinese companies’ potential for innovation and growth, particularly as they presented an array of cutting-edge products ready for global markets. This positive perception reflects a growing confidence in China's healthcar...
Greater China Sector Update | Healthcare At the recent investor conference, global investors viewed Chinese healthcare companies with increasing interest and optimism. Impressed by their advanced R&D pipelines and swift R&D-to-market execution capabilities, investors recognised Chinese companies’ potential for innovation and growth, particularly as they presented an array of cutting-edge products ready for global markets. This positive perception reflects a growing confidence in China's healthca...
We expect 4Q25 to be characterised by moderation in NIM compression, sustainable growth in wealth management fees and benign asset quality. We project net profit of S$2,523m for DBS (flat yoy, -15% qoq) and S$1,747m for OCBC (+4% yoy, -12% qoq). Maintain OVERWEIGHT. BUY DBS (Target: S$68.95) and OCBC (Target: S$23.65). DBS provides an attractive 2026 dividend yield of 5.6%. We are excited to hear the new CEO’s strategy, priorities and vision for OCBC.
Top Stories Sector Update | Banking We expect 4Q25 to be characterised by moderation in NIM compression, sustainable growth in wealth management fees and benign asset quality. We project net profit of S$2,523m for DBS (flat yoy, -15% qoq) and S$1,747m for OCBC (+4% yoy, -12% qoq). Maintain OVERWEIGHT. BUY DBS (Target: S$68.95) and OCBC (Target: S$23.65). DBS provides an attractive 2026 dividend yield of 5.6%. We are excited to hear the new CEO’s strategy, priorities and vision for O...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.